Tag Archive for: Investment

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies

/in

Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed Fund to be listed on public markets in due course […]

Read more

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

/in

Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP) Scale Up call Funding to support commercialization of its groundbreaking bioresorbable vascular conduits EINDHOVEN, The Netherlands, 8 April 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and […]

Read more

Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform

/in

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors Mikkel Wandahl Pedersen […]

Read more

This week’s hot topic: Life sciences industry on high alert as Rachel Reeves’s crucial budget looms

/in

By Richard Staines, Optimum Strategic Communications It’s just two weeks until the Labour government announces its crucial first budget, which will set the tone for Keir Starmer’s term as prime minister.  The government has been busy making its excuses ahead of the announcement. With talk of a £22 billion “Black Hole” in public finances blamed […]

Read more

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

/in

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Read more